# Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

> **NCT00851721** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 52 (actual)

## Conditions studied

- Hemophilia A or B With Inhibitors
- Hemophilia A
- Hemophilia B

## Interventions

- **BIOLOGICAL:** Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
- **BIOLOGICAL:** Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)

## Key facts

- **NCT ID:** NCT00851721
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-31
- **Primary completion:** 2012-10-17
- **Final completion:** 2012-10-17
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851721, "Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00851721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*